Status:
COMPLETED
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CP...
Eligibility Criteria
Inclusion
- Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for \>6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
- Availability of tissue sample.
Exclusion
- Pregnant, lactating, or intending to become pregnant during the study.
- Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.
Key Trial Info
Start Date :
February 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03333655
Start Date
February 16 2018
End Date
August 4 2022
Last Update
August 12 2022
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Comp Canc Ctr
San Francisco, California, United States, 94115
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology
St Louis, Missouri, United States, 63108
4
Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion
New York, New York, United States, 10032